A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia
about
Neuroinflammation and psychiatric illnessMinocycline: therapeutic potential in psychiatryAddressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment optionsA review of anti-inflammatory agents for symptoms of schizophreniaLyme disease and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS): an overviewCelecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On TrialsToward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ RegimenMicroglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric DisordersStress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illnessA New Outlook on Mental Illnesses: Glial Involvement Beyond the GlueStress-Related Immune Markers in Depression: Implications for TreatmentCognitive remission: a novel objective for the treatment of major depression?The role of inflammation in schizophreniaInflammation and immunity in schizophrenia: implications for pathophysiology and treatmentNeuron-glia interaction as a possible glue to translate the mind-brain gap: a novel multi-dimensional approach toward psychology and psychiatryThe neuroimmunology of schizophreniaProfile of minocycline and its potential in the treatment of schizophreniaThe cytokine model of schizophrenia: emerging therapeutic strategiesInflammation and schizophreniaMinocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatmentEfficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an updateMinocycline modulates human social decision-making: possible impact of microglia on personality-oriented social behaviorsGABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism.Preventive effects of minocycline in a neurodevelopmental two-hit model with relevance to schizophrenia.Viral infection, inflammation and schizophreniaMissing and Possible Link between Neuroendocrine Factors, Neuropsychiatric Disorders, and MicrogliaL-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study.Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?Neuroimmunological aberrations and cerebral asymmetry abnormalities in schizophrenia: select perspectives on pathogenesisEvidence for an immune role on cognition in schizophrenia: a systematic reviewOpen-label add-on treatment trial of minocycline in fragile X syndrome.Immunological aspects of the treatment of depression and schizophrenia.Methylation patterns in whole blood correlate with symptoms in schizophrenia patients.Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathwaysA novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation [corrected] factor eIF4AI.Cognitive neurosciences: A new paradigm in management and outcome of schizophreniaCognitive enhancers in the treatment of substance use disorders: clinical evidence.The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Microglial dysregulation in psychiatric disease
P2860
Q21245244-0A140C3A-8FE5-4D9F-BBB5-475FA3BC6B73Q22241418-FC87F523-592A-442D-9501-B02E49F63B16Q22241447-26366AF1-5CCC-433C-ADAF-08CE2B61B739Q22241827-20DBDA2C-369B-45E3-9836-D4BAEA895693Q24626864-E4F54A1B-EC1D-481B-BC85-7BB78A8C4F8AQ26741541-7AD1267F-AF30-472A-B31F-EBCD3E58B44AQ26749972-407D2E8B-FE86-4B3E-A33B-3AEE87153EBEQ26767489-9E2B27C4-5D61-444A-A149-AFAF9221D2C6Q26769004-628954AB-AC11-417D-A685-90B7751A1FA6Q26770756-914FD433-D096-41C9-85BC-5393124C9CF8Q26771607-2E92D524-EDE2-4131-ABE6-3D77E41B089DQ26775386-F76BFF2E-AF49-4BD2-8E71-53D1E5AA6347Q26779719-A81F6022-6FB8-4C0D-A79C-C9B2D3C6198FQ26781620-1FC17CCA-D389-4C83-992F-6423B41F2625Q26825959-0B70DB60-3108-44F3-9C95-79432FEECBB0Q26859392-1D04C41A-8F68-4D59-9347-3B7876DCD07AQ26864400-4E8A4C3C-6680-483C-8A92-201619FC3D78Q26865996-99B00D74-FA01-49FD-8901-1BC832B7F5ADQ27002489-934B8CA0-331C-4327-B1EE-2865EE6271AAQ28265163-3F653F9B-CB27-4910-90EB-D76248E7D932Q28299995-9ADADF0F-62F2-46BD-BE06-D9FF8C3AE9D1Q28481316-4E751E2F-4067-4905-B3ED-0C951357B23BQ30363617-11D9AC65-0E74-45A1-8A22-B5B1B77F594BQ30383068-6EE7E02F-FB3C-4B35-B129-A05254828DCEQ30440507-6691F8A8-DE7D-43CD-8AE9-7AE0962428C8Q30452038-3457B7EC-2614-4F7A-AC3F-2B1D8B14F861Q30475497-CEA82FF1-B893-48DB-8BFD-E66AF7D73B48Q30536299-80E54608-339C-48C9-92AE-093F7F030BEDQ33618965-2EC9954E-69F2-43B4-A9A2-4456237799CFQ33621692-681E752E-365A-4E27-AF69-538A5951DE4BQ33715073-AE1FB89D-05F9-491C-963E-061542C938B6Q33721031-647D17AA-B75E-4444-B24B-AF6A4AEE5508Q33762454-474D5677-802D-4895-B4DA-3EF68611D7CFQ33762512-D45267AA-DBD8-4FA5-ACA5-23855D6969B2Q33769000-AFC1C184-FDD2-4942-B8A7-FA84C02E3B54Q34082617-EDD87C69-119C-420C-A7FC-99599DDBEB81Q34183988-D8469A80-EDD4-42AE-8292-4043C49E2DB7Q34213731-ED5A96B0-FD91-40CD-BE7E-4B20D60EEA2DQ34274859-3DDB75C3-7469-495E-BB8B-64DFDD85C13FQ34345744-8B49B43D-D06A-462F-B3CD-E200F7CFCD12
P2860
A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
A double-blind, randomized stu ...... s in early-phase schizophrenia
@ast
A double-blind, randomized stu ...... s in early-phase schizophrenia
@en
A double-blind, randomized stu ...... s in early-phase schizophrenia
@nl
type
label
A double-blind, randomized stu ...... s in early-phase schizophrenia
@ast
A double-blind, randomized stu ...... s in early-phase schizophrenia
@en
A double-blind, randomized stu ...... s in early-phase schizophrenia
@nl
prefLabel
A double-blind, randomized stu ...... s in early-phase schizophrenia
@ast
A double-blind, randomized stu ...... s in early-phase schizophrenia
@en
A double-blind, randomized stu ...... s in early-phase schizophrenia
@nl
P2093
P3181
P356
P1476
A double-blind, randomized stu ...... s in early-phase schizophrenia
@en
P2093
Hana Levkovitch-Verbin
Ilan Treves
Sharon Riwkes
Shlomo Mendlovich
Shmuel Fennig
Shmuel Kron
Yechiel Levkovitz
Yoram Braw
P304
P3181
P356
10.4088/JCP.08M04666YEL
P407
P577
2010-02-01T00:00:00Z